20 November 2025 We’re pleased to announce three new interactive dashboards for researchers working in Type 1 diabetes: UKT1D Selected Publications and Thought Leading Reviews – Access our comprehensive collection of publications and influential reviews from the consortium. Facts and Figures about the UKT1D – Explore key statistics and analytics about our reach, impact, and contribution […]
Date: 19 November 2025 World Diabetes Day 2025 has brought encouraging news for the type 1 diabetes community. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of teplizumab (Tzield) for patients with stage 2 type 1 diabetes. This marks a significant milestone as […]
Date: 14.11.2025 The European Association for the Study of Diabetes (EASD) is accepting applications for its inaugural Immunology School for Endocrinology, taking place on 26-27 March 2026 in Vienna, Austria. This two-day educational programme offers an excellent opportunity for researchers and clinicians working in diabetes and endocrinology to deepen their understanding of immunological mechanisms. How […]
A groundbreaking clinical trial has shown that the drug teplizumab can delay the onset of type 1 diabetes by an average of two years in high-risk individuals. The treatment, which targets the immune system, offers hope for those identified as being at risk of developing the condition. Researchers describe it as a “pivotal moment” in […]
Type 1 diabetes (T1D) research is at a pivotal point – there is now a licensed therapy in the UK, Teplizumab, to delay onset of symptoms in people with early stage T1D (Link). Over decades, our UK-based research, both academic and commercial has made a major contribution to identifying children and adults who will develop […]
A new drug for Type 1 diabetes, Teplizumab, is being tested in the PROTECT clinical trial. Teplizumab blocks the action of insulin-destroying antibodies in type 1. Read the article on the Daily Mail
The ELSA study launched nationally on World Diabetes Day in November 2022. Within 24 hours, over 1000 children were signed-up to the study! By February 2023, we have sent over 3000 home-testing kits out to families and have analysed over 1000 kits so far. The next phase of the study is to disseminate to schools […]
Study shows verapamil can have a beneficial effect on the pancreas in children with newly diagnosed type 1 diabetes. Find out more from this article
On 17/11/22 teplizumab was approved by the US Food and Drug Administration (FDA) as the first ever treatment indicated to delay the onset of stage 3 type 1 diabetes. This is the biggest treatment breakthrough for the condition since the discovery of insulin 100 years ago. Although teplizumab is not approved in the UK yet, […]
An 11 year old’s story of taking part in immunotherapy research: Mahn was diagnosed with type 1 diabetes in May 2020. His parents Sharon and Harj were determined to get him onto a clinical trial testing a new treatment called immunotherapy, which hopes to slow the immune attack behind type 1 diabetes. Please click the […]
Moving towards insulin-free T1D